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ABSTRACT
Objective: The aim of this study was to formulate a new developed solid dispersion (SD) containing fixed dose combination of nalidixic acid and 
cefdinir (500:300 mg) to improve dissolution rate of poorly soluble drugs via a new mechanism as well as the conventional mechanism of SD 
represented by the presence of hydrophilic carrier.
Methods: Through this objective eight newly developed SD formulas of fixed dose combination of nalidixic acid and cefdinir (500:300 mg) and 
(polyethylene glycol 6000 and poloxamer 188) in different ratio were prepared, in addition to SD of each drug alone and simple mixture of individual 
SD (SMSD) prepared by means of fusion technique. Moreover, SDs beside pure drugs, simple mixture, and physical mixture (PM) were characterized 
by dissolution tests, solubility studies, powder X-ray diffractometer (PXRD), differential scanning calorimetry (DSC), Fourier transform-infrared 
(FT-IR) spectroscopy and scanning electron microscopy (SEM).
Results: From in vitro dissolution tests, PXRD, DSC, FT-IR, and SEM; it is indicated the presence of a physical complex between cefdinir and nalidixic 
acid in their SD containing combination of fixed dose of both drugs. This will affect the crystallinity of the second drug and their dissolution behavior 
in addition to the conventional mechanism owing to the presence of hydrophilic carrier (poloxamer 188).
Conclusion: It was concluded that the newly prepared formula of SD containing fixed dose combination of nalidixic acid and cefdinir will be promising 
for higher dissolution profile than that from SD of each drug alone or SMSD of each drug.
Keywords: Nalidixic acid, Cefdinir, Poloxamer 188, Polyethylene glycol 6000, Combinational solid dispersion, Fusion method.
INTRODUCTION
Diverse methods applied to improve solubility of poorly water-
soluble drugs including salt formation, complexation, micronization, 
micellar solubilization, use of surfactant, cosolvency, use of prodrug, 
drug derivatization, pH alteration, chemical modification, solid 
dispersion (SD), hydrotrophy, and others [1]. SD is one of the most 
viable and economic promising approaches that represent an ultimate 
challenge to the formulation scientists in the pharmaceutical industry, 
clinical application, and marketability employed to improve the 
oral bioavailability of poor water soluble drugs whose absorption is 
dissolution rate limited [2]. SD is accomplished through reducing drug 
particle size to the absolute minimum, increasing porosity, converting 
the crystalline forms of drug into amorphous form and hence 
improving drug wettability. SD refers to the dispersion of one or more 
active ingredient in an inert carrier or matrix at solid state prepared by 
melting (fusion), solvent, or the melting solvent method [3,4].
Combination of more than one active ingredient is referred to as 
combination SD, where the possibility of the presence of one drug may 
affect the solubility of another one [5]. To investigate such possibility; 
nalidixic acid and cefdinir are used where such combination therapy 
is commonly applied for treatment of many infectious diseases such 
as urinary tract infection [6,7]. Nalidixic acid (class II) is a quinolone 
group drug that has a high bacteriostatic and bactericidal activity 
against infections caused by Gram-negative organisms. It is a drug with 
poor aqueous solubility often low absorption and poor bioavailability. 
Thus improvement in aqueous solubility and dissolution rate are 
necessary [8]. Cefdinir (class IV) is an oral extended spectrum antibiotic 
which belongs to third generation cephalosporins with low solubility and 
low permeability resulting in a low oral bioavailability characteristic [9].
This study was undertaken to investigate the feasibility and efficacy 
of formulating SD containing fixed dose combination of nalidixic acid 
and cefdinir on their solubility/dissolution profile in comparison to SD 
containing each drug separately and simple mixture of their individual 
SDs in addition to physical mixture (PM) of the two pure drugs. The 
proposed combination SD technology may improve the absorption rate 
of the poorly soluble drugs and suggesting an additional mechanism to 
enhance drug dissolution via SD technology.
MATERIALS AND METHODS
Materials
Nalidixic acid (Sigma Chemical Co. [Aldrich], USA), cefdinir (Buchang 
Pharma, China), poloxamer 188 (M/S Provizer Pharma, India), 
polyethylene glycol 6000 (PEG 6000) (Sigma Chemical Co. (Aldrich), 
USA).
Methodology
Preparation of combination SDs containing fixed dose of nalidixic 
acid and cefdinir
The recommended dose for nalidixic acid is 500 mg and for cefdinir is 
300 mg. accordingly, SDs containing combination of nalidixic acid and 
cefdinir (500:300 mg) were prepared using fusion method. Nalidixic 
acid and cefdinir (SD1-SD8) as showed in (Table 1) were added to 
the molten carrier (poloxamer 188 or PEG 6000) in a water bath at 
60°C, with continuous stirring for 15 minutes until a homogenous 
dispersion was formed. The dispersion was then left to solidify at room 
temperature, and then samples were passed through an 80-mesh sieve 
and kept in well-closed glass containers in a desiccator for further 
studies [10].
© 2017 The Authors. Published by Innovare Academic Sciences Pvt Ltd. This is an open access article under the CC BY license (http://creativecommons. 
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Preparation of SD of nalidixic acid and cefdinir each separately
SD containing nalidixic acid 500 mg containing (SD9) or cefdinir 
300 mg (SD10) with poloxamer 188 in ratio (1:6) was prepared by 
fusion method as mentioned earlier [10] and showed in (Table 1).
Preparation of simple mixture of individual SDs (SMSDs)
A mixture was prepared by simple mixing of the previously prepared 
nalidixic acid SD9 and cefdinir SD10 in a mortar for 5 minutes until a 
homogenous mixture was obtained. The resulting mixture SMSD was 
then sieved [11].
Preparation of physical mixture (PM) of nalidixic acid and cefdinir
PX of pure nalidixic acid and pure cefdinir powder (500:300 mg) (PM) 
was prepared by mixing them with poloxamer 188 in ratio (1:6) for 
5 minutes in a mortar until a homogenous mixture was obtained. The 
resulting mixture was then sieved. The powder was kept in well-closed 
glass container in desiccators for further analysis [12].
Evaluation of SDs
In vitro dissolution testing
Dissolution test was performed for pure powders of nalidixic acid and 
cefdinir for combination SD of nalidixic acid and cefdinir (SD1-SD8), 
SD containing each drug separately (SD9 and SD10), SMSD, and PM 
of pure drugs in the presence of Poloxamer 188; using the dissolution 
apparatus (Copley - UK) Type II paddle method with rotation speed 
50 rpm for 90 minutes. The dissolution medium was 900 ml phosphate 
buffer pH 6.8 thermo-stated at 37±0.5°C. Five milliliters samples 
were withdrawn after specific time intervals filtered before analysis 
and equal volumes of fresh phosphate buffer, maintained at 37°C, 
were added to the dissolution medium to maintain sink condition. 
The release of nalidixic acid and cefdinir was assayed by ultraviolet 
spectrophotometer (Shimadzu 1650 pc-Japan) at 257 nm and 287 nm, 
respectively, and quantified using a calibration curve in the same 
media [13,14].
All samples were analyzed in triplicate, and release curves were plotted 
using calculated mean values of % cumulative drug release.
Saturated solubility studies
Saturated solubility in phosphate buffer pH 6.8 was applied for 
nalidixic acid and cefdinir from the prepared combination SD7, SD 
containing nalidixic acid and cefdinir (SD9 and SD10), SMSD; in 
comparison to solubility from the pure powders of each drug as well 
as from PM of the two pure drugs with Poloxamer 188. The study was 
conducted in thermostatic shaker bath for 48 hrs at 37±5°C. Finally, 
the solutions were filtered and the filtrate was diluted for determining 
drug concentration spectrophotometrically, the absorbance was 
measured at 257 nm for nalidixic acid and 287 nm for cefdinir [15].
Powder X-ray diffraction (PXRD)
PXRD patterns for each of pure powders of nalidixic acid and cefdinir, 
combination SD7, SD containing each drug separately (SD9 and SD10), 
SMSD, and PM of pure drugs in the presence of Poloxamer 188 were 
recorded for structural and crystal size characterization using PXRD 
(Shimadzu 6000, Japan) under the following conditions. Nickel-filtered 
CU-Kα radiation (λ=1.54060 Å). The voltage and current was 40 KV 30 mA, 
respectively, and smoothed 90. Measurement was carried out in the range 
5° and 60° using a step size of 0.05° and 0.6 seconds per step [16].
Thermal analysis
Differential scanning calorimetry (DSC) curve for each of pure powders 
of nalidixic acid and cefdinir, combination SD7, SD containing each drug 
separately (SD9 and SD10), SMSD, and PM of pure drugs in the presence 
of Poloxamer 188 were measured with a DSC instrument (DSC-60, 
Shimadzu - Japan). The samples were accurately weighed and heated 
in sealed aluminum pan at a rate of 10°C/minutes between 30°C and 
250°C under a nitrogen gas flow of 40 mL/minutes during the study. 
Empty iridium pan was used as a reference [17].
Fourier transform-infrared (FT-IR) spectroscopy
FT-IR spectra for each of pure powders of nalidixic acid and cefdinir, 
poloxamer 188 also for combination SD7, SD containing each drug 
separately (SD9 and SD10), SMSD, and PM of pure drugs in the 
presence of Poloxamer 188 recorded by FT-IR spectrophotometer 
(8400S, Shimadzu - Japan) using potassium bromide pellets. The 
samples were scanned from 4000 to 400/cm. The compatibility of 
drug in the formulation was confirmed by IR spectra of pure drugs and 
formulations were determined [18].
Scanning electron microscopy (SEM)
The SEM analysis was carried out for each of pure powders of nalidixic 
acid and cefdinir, poloxamer 188, also for combination SD7 and SMSD 
using SEM (Inspect S50, FEI - Netherland). Before examination, samples 
were mounted on an aluminum stub using a double sided adhesive tape 
and then making it electrically conductive by coating with a thin layer 
of gold (approximately 24 nm) in vacuum. The SEM was operated at an 
acceleration voltage of 10 KV [19].
RESULTS AND DISCUSSION
In vitro dissolution studies
It was evident that the pure nalidixic acid exhibited a slow dissolution 
in phosphate buffer pH 6.8 as showed in (Figs. 1 and 2), where the 
percentage of drug dissolved after 90 minutes was 60.09%. This is due 
to its hydrophobicity and poor wettability; leading to agglomeration of 
nalidixic acid particles and floating of drug powder on the surface and 
consequently hindering its dissolution [20].
All combinational SD formulas (SD1-SD8) showed a significant 
enhancement in nalidixic acid release (p<0.05) compared to the pure 
Table 1: Formulations of SD prepared and their compositions
Formula number Drug: Nalidixic acid (mg) Drug: Cefdinir (mg) Carrier: PEG 6000 (mg) Carrier: Poloxamer 
188 (mg)
Drug: Carrier ratio
SD1 500 300 1600 1:2
SD2 500 300 3200 1:4
SD3 500 300 4800 1:6
SD4 500 300 6400 1:8
SD5 500 300 1600 1:2
SD6 500 300 3200 1:4
SD7 500 300 4800 1:6
SD8 500 300 6400 1:8
SD9 500 3000 1:6
SD10 300 1800 1:6
SMSD 500 300 4800 1:6
PM 500 300 4800 1:6
SD: Solid dispersion, SMSD: Simple mixture of individual solid dispersion, PM: Physical mixture of nalidixic acid: cefdinir: poloxamer
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drug. Formulations containing PEG 6000 as a hydrophilic carrier 
(SD1-SD4) showed a significant increase (p<0.05) in the dissolution 
rate with increasing its concentration. A best release obtained for 
(SD3) after 90 minutes was 90.95% where the drug to polymer ratio 
was 1:6. As a suggested mechanism; the presence of PEG 6000 as 
a hydrophilic carrier improves drug wettability and causes rapid 
penetration of the dissolution medium into the particles. On increasing 
PEG 6000 concentration (SD4), the release of nalidixic acid slightly 
decreased than that of (SD3) due to the formation of viscous boundary 
layer around the drug particles that slows down its diffusion into the 
dissolution medium [21].
Formulations prepared with poloxamer 188 as a hydrophilic carrier 
(SD5-SD8) showed a higher dissolution rate than those prepared 
with PEG 6000 and formula (SD7) showed maximum drug release; 
where it is 95.02% in 90 minutes. This may be attributed to the 
surfactant property of poloxamer (micellar solubilization) and its great 
hydrophilicity resulting in a greater wettability of the drug. However, 
higher concentration of poloxamer 188 (SD8) led to slight decrease in 
dissolution rate in comparison to (SD7). This is related to the gelling 
property of the polymer at higher concentration which increases the 
viscosity of the diffusion boundary layer adjacent to the dissolving 
surface [22].
Figs. 3 and 4 showed that there was no significant difference in the 
dissolution of cefdinir from the prepared formulas (SD1-SD8) in 
comparison to dissolution of pure drug since cefdinir is highly soluble 
in phosphate buffer pH 6.8 where it is highly soluble.
Accordingly, the dissolution of drug from (SD7) for combinational 
SD containing nalidixic acid and cefdinir in the presence of 1:6 ratio 
of poloxamer was compared to their dissolution from their individual 
SD (SD9 and SD10), SMSD and PM of pure drugs in the presence of 
Poloxamer 188. Based on the drug dissolution profiles; formula (SD7) 
selected to be the optimum formula.
The release of nalidixic acid (Fig. 5) from the optimum formula (SD7) 
and (SMSD) was significantly (p<0.05) greater than that from (SD9) and 
(PM). While there was no significant change in the dissolution profile 
of cefdinir (Fig. 6) from all formulas; in which cefdinir shows high 
release from all these formulas [14]. The release of nalidixic acid from 
(SD7) which contains combinational SD of nalidixic acid and cefdinir 
was slightly higher than that from (SMSD). These results suggest 
an additional mechanism of increasing solubility and dissolution of 
nalidixic acid in SD. It may be attributed to the solvent effect of cefdinir 
on nalidixic acid. Nalidixic acid was dispersed in cefdinir matrix in 
Fig. 1: Dissolution profiles of nalidixic acid from the combination 
solid dispersions (SD) using polyethylene glycol 6000 as carrier 
(SD1-SD4) and pure nalidixic acid (n=3) (mean±standard 
deviation)
Fig. 2: Dissolution profiles of nalidixic acid from the combination 
solid dispersions (SDs) using poloxamer 188 as a carrier (SD5-SD8) 
and pure nalidixic acid (n=3) (mean±standard deviation)
Fig. 3: Dissolution profiles of cefdinir from the combination solid 
dispersions (SDs) using polyethylene glycol 6000 (SD1-SD4) and 
pure cefdinir (n=3) (mean±standard deviation)
Fig. 4: Dissolution profiles of cefdinir from the combination solid 
dispersions (SDs) using poloxamer 188 (SD5-SD8) and pure 
cefdinir (n=3) (mean±standard deviation)
Fig. 5: Dissolution profiles of nalidixic acid from the combination 
solid dispersion (SD) SD7, SD containing drug separately (SD9), 
physical mixture (PM), and simple mixture of individual SD 
(SMSD) (n=3) (mean±standard deviation)
Fig. 6: Dissolution profiles of cefdinir from the combination 
solid dispersion (SD) SD7, SD containing drug separately (SD10), 
physical mixture and simple mixture of individual SD (SMSD) 
(n=3) (mean±standard deviation) 
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amorphous or solid solution in SD, and on exposure to dissolution 
medium, the matrix dissolves and releases the dispersed drug in a pure 
state of subdivision which facilitates dissolution of nalidixic acid [23]. 
This is added to the conventional mechanism observed in SD prepared 
using hydrophilic carrier of poloxamer [24].
Saturated solubility studies
The results of saturated solubility of nalidixic acid and cefdinir from 
formulations (SD7, SD9, SD10, SMSD, and PM) and pure drugs in 
phosphate buffer pH 6.8 are presented in Table 2.
It was observed that the saturated solubility of nalidixic acid from 
optimum combinational SD7 was about two-fold higher than that from 
simple mixture of individual solid dispersion of both drugs (SMSD) 
suggesting the presence of a physical complex between nalidixic and 
cefdinir, such complex observed during the method of preparation 
of the (SD7) formulas where the temperature used in fusion method 
enhanced such complex in the solid state as well as in the liquid 
state. In addition to the solvent effect of cefdinir that was observed 
in the dissolution study. Solid state complex is reported for SD of 
hydrochlorothiazide - losartan potassium [23].
No significant increase in solubility of cefdinir in phosphate buffer 
pH 6.8 from all the prepared formulas due to its high ionization in this 
pH (Table 3) [25].
PXRD
The PXRD patterns for each of pure powders of nalidixic acid and 
cefdinir, SD7, SD9, SD10, SMSD, and PM are showed in (Fig. 7).
The spectrum of pure nalidixic acid and pure cefdinir showed a 
higher number of reflections of higher intensity. Thus, PXRD pattern 
of pure nalidixic acid showed a numerous sharp distinctive, narrow 
and strongly intense diffraction peaks that represent a highly stable 
crystalline nature of the drugs [26,27].
On the other hand, the PXRD of (SD7 and PM) showed decrease in the 
intensity of peaks and disappearance of some sharp distinctive peaks 
for (SD7) in comparison to (PM) and pure drugs and the formation of 
broadened peaks as an evident of decrease in degree of crystallinity 
and predict for the amorphous form appearance compared to the pure 
powders of both drugs. This can be attributed to the change in the 
orientation during the crystal growth phase leading to formation of 
imperfect crystals or amorphonization that will dissolve at fastest rate due 
to higher internal energy and greater molecular motion which develop 
thermodynamic properties relative to crystalline materials [28,29].
Table 2: Saturated solubility of nalidixic acid in comparison to 
solid dispersion formulas, SMSD and PM
Formulation Nalidixic acid solubility (mg/ml)





Saturated solubility data represent (mean±SD) (n=3). SD: Solid dispersion, 
SMSD: Simple mixture of individual solid dispersion, PM: Physical mixture
Table 3: Saturated solubility of pure cefdinir in comparison to 
SD formulas, SMSD and PM






Saturated solubility data represent (mean±SD) (n=3). SD: Solid dispersion, 
SMSD: Simple mixture of individual solid dispersion, PM: Physical mixture
Fig. 7: Powder X-ray diffraction patterns of (a) pure nalidixic acid, 
(b) pure cefdinir, (c) SD7, (d) physical mixture (PM), (e) SD9, (f) 
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Formulas (SD9, SD10, and SMSD) showed shift in the number and 
intensities of peaks in PXRD than the pure drugs, the base of the peaks 
in (SD9, SD10, and SMSD) were also found to be boarder in nature 
but less extent than that observed with (SD7) resulting a change in 
crystallinity [30,31]. Therefore, the results obtained from PXRD agreed 
with that of dissolution study where (SD7) showed high drug release.
Thermal analysis
As showed in (Fig. 8), DSC thermogram of nalidixic acid and cefdinir 
presents a sharp endothermic peak at 228°C and 155°C, respectively, 
corresponding to their melting points. Similarly, the DSC curve of 
poloxamer 188 shows one endothermic effect, associated with its 
melting at 56.7°C.
The DSC thermograms of SDs (SD9, SD10, and SMSD) gave boarder peak 
for polymer with shifted position than that of pure polymer indicating 
miscibility of drug with the polymer. Furthermore, it showed board 
peak for cefdinir and nalidixic acid indicating the amorphous structure 
in these formed SD (SD9, SD10, and SMSD). The absence of endotherm 
in PM suggested the dissolution of the crystalline drug particles within 
the molten polymer due to the heating phase during analysis [32]. While 
(SD7) showed wide endothermic peak at 46.74°C with disappearance 
Fig. 8: Differential scanning calorimetry thermograms of (a) pure cefdinir; (b) pure nalidixic acid; (c) poloxamer 188; (d) SD9; (e) SD10; 
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of end peaks for cefdinir and nalidixic acid, suggesting a complex 
formation between cefdinir and nalidixic acid within SD formula that 
may give new peak for such complex melting point and this supporting 
the interpretation obtained from dissolution study [33,34].
FT-IR spectroscopy
The IR spectrum of pure nalidixic acid powder as showed in (Fig. 9a) 
is characterized by principle absorption bands at 3043.77/cm, 
2983.98/cm (C-H stretching vibrations), 1785/cm (C=N stretching 
vibrations), 1712.85/cm (C=O asymmetric stretching vibrations), 1616.4/cm 
(c-c asymmetric stretching vibrations) and 1518.03/cm(c-c symmetric 
bending), 1473.66, 1440.87 (C-N stretching), 1352.14 and 1327.07/cm 
(N-C-H deformation), 1253.77/cm (CH3 bending), 1228.7/cm (C-O-H 
symmetric bending), 1130.32, 1101.39, 1051.24, 1004.95 and 972.16/cm 
(C-C-H asymmetric and symmetric bending vibrations), 804.34/cm (O=C-C 
asymmetric bending), 656 and 635/cm (C-C-C bending), 455/cm, 485/cm, 
400/cm (CN=C, N-C-N, and C-N-C bending vibrations) [35].
The IR spectrum of pure cefdinir powder as showed in (Fig. 9b) is 
characterized by absorption peaks at 3360/cm (N-H stretching vibration 
of amide group) while NH2 group appears symmetrical and asymmetrical 
stretching at 3298.8/cm, the band 3070.78/cm due to aromatic (C-H), 
2968.55/cm and 2877.89/cm (aliphatic C-H), 1766.85/cm and 1683.91/
cm (carbonyl group), 1624.12/cm (C-O stretch, asymmetric and 
symmetric in COOH), 1595.18/cm and 1558.54/cm (C=N), 1519.96 (N-H 
bending amide II band) and 1352.14 (NH2 bending vibration) [36].
The IR spectrum of poloxamer 188 as showed in (Fig. 9c) is characterized 
by principal absorption peaks at 2883/cm (C-H stretch aliphatic), 
1341/cm(in-plane O-H bend) and 1099/cm (C-O stretch), which 
were consistent in all binary systems with the drug. The IR spectrum 
of (SD7) as shown in (Fig. 9d) illustrates the presence of all nalidixic 
acid and cefdinir peaks with decreased intensity and smoothened thus 
indicating a strong physical complex between both drugs due to inter-
molecular hydrogen bonding in SDs [37].
FT-IR spectrum of (SMSD) as showed in (Fig. 9e) demonstrates the lack 
of any new peaks in the SD and also no differences in the position of 
absorption bands, indicating the absence of significant interactions 
between both drugs and carrier [38].
Fig. 9: The FT-IR spectra for (a) pure nalidixic acid powder; (b) pure cefdinir powder; (c) poloxamer 188; (d) SD7; (e) simple mixture of 
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FT-IR spectrum of the (PM) as showed in (Fig. 9f) displayed the 
superimposition pattern of both drugs and polymer peaks with 
decreased peak intensity and little shifting of the peaks during cogrinding 
revealing the inert nature of the carrier used for formulation [39].
The IR spectrum of SD9 and SD10 as showed in (Fig. 9g and 9h), 
respectively; presented all characteristic bands are well defined and 
appeared clear in the spectrum with no change in frequency and 
shape of bonds, which suggested that no significant redistribution of 
electronic density in the structure of the organic molecule appeared. 
This indicated that there is no strong interaction between each drug and 
polymers in each formula [40]. This study agreed with our conclusion 
obtained in PXRD, DSC, and dissolution study.
SEM
SEM of pure nalidixic acid powder and pure cefdinir powder showed 
crystal form and poloxamer 188 showed globular forms as showed in 
(Fig. 10). In SD of fixed dose combination (SD7) and SMSD; the structure 
of both drugs crystal is completely different from the pure drug. These 
findings demonstrated that the drug was changed in amorphous form 
which was confirmed by our PXRD and DSC studies [41].
From the results of PXRD, FT-IR, SEM, and DSC; it is indicated the 
presence of a physical complex between cefdinir and nalidixic acid in 
their SD containing combination of fixed dose of both drugs that affect 
the crystallinity of the second drug and their dissolution behavior 
in addition to the conventional mechanism due to the presence of 
hydrophilic carrier (poloxamer 188).
CONCLUSION
From the previous studies, it was noticed that the optimal formula 
(SD 7) has led to the possibility of preparation of SD containing fixed 
dose combination of nalidixic acid and cefdinir. A higher dissolution 
profile is approved than that from SD of each drug alone or SMSD of 
each drug. This suggesting a new mechanism for drug dissolution that 
involves a physical complex between nalidixic acid and cefdinir that 
have higher dissolution rate than each drug alone and even higher than 
SD containing each drug alone. Such complex present in the solid state 
and in the solution state in addition to action of cefdinir that may act as a 
solvent (a new carrier) for nalidixic acid; thus improving its dissolution, 
as well as the conventional mechanism for SD that is represented by the 
existence of poloxamer 188 as a (hydrophilic carrier).
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